The AUTOSTEM consortium is a multi-disciplinary mix of engineers, regenerative medicine scientists and high-tech companies.
- The project is led by Dr Mary Murphy of the National University of Ireland, Galway.
- The cell extraction device is being developed by Irish SME Crospon. Critically, Crospon has experience of designing, building and validating CE-approved devices in the past. This makes the learning curve (and risk) of the device less challenging.
- The automated pipeline is built by the Fraunhofer Institute for Production Technology (IPT) in Aachen. It will benefit greatly from IPT’s experience in an earlier project (‘StemCellFactory’) where a similar pipeline was developed.
- Cell isolation technology is provided by Irish SME Orbsen Therapeutics, who have unique capabilities and IP in the prospective isolation of stem cells from bone marrow and other cell types.
- The bio-reactors will be provided by German SME ZellWerk (Berlin), and by the University of Aston, (Birmingham) in the UK. An important part of the project is to examine different options for large-scale cell production.
- Sensor technology for controlling the cell culture environment is being developed by the Tyndall Institute, at University College Cork, in Ireland.
- The cells produced by the pipeline will be tested and validated, to verify that they act as stem cells are expected to do, by the University of Genoa, Italy.
- Risk assessment, health economics and process optimisation for the end-to-end project is supported by researchers from the UK’s Cell Therapy Catapult.
- Administration, dissemination activity and exploitation planning are supported by Irish SME Pintail (Dublin).